Jared D. W. Price

This paper uses patient-derived pancreatic cancer organoids to identify drug sensitivities linked to tumor differentiation and pathway mutations, revealing new therapeutic targets in chemoresistant tumors.

The paper identifies synthetic dosage lethality targets for PLK1-overexpressing cancers using genome-wide screens and validates key hits to show their therapeutic potential.

This study identifies Neurog2 as a potential therapeutic target for MYCN-driven neuroendocrine prostate cancer by showing its role in promoting tumor growth and NEPC development.

The paper identifies FTSJ3 as a critical vulnerability in hTERT-overexpressing cancers by showing its role in TERRA methylation and telomeric heterochromatin stability.